CClinicalTrials.gg
CompletedNCT06561750Updated Aug 20, 2024

The Effect of Aspalathus Linearis on Muscle Soreness and Post-exercise Recovery in Young, Physically Inactive Women

An interventional study of Rooibos tea and Control in Inflammation, Muscle Recovery and Muscle Soreness, sponsored by Hasselt University. Completed at 1 site in Belgium. Open to female participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-20.

Sponsored by Hasselt University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2023, registered Feb 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
Female
01

Study summary

Exercise has been found to exert beneficial effect on overall health. However, it also induces muscle damage at the same time. This then leads to muscle pain, temporary inflammation and reduced muscle function. These symptoms can persist for up to 72 hours after physical exertion and thus have a negative impact on a speedy recovery. Research has previously shown that antioxidants play an important role in muscle recovery after physical exertion. For example, antioxidants are known to have a positive effect on muscle damage and muscle soreness, and they also provide an anti-inflammatory effect. An important group of antioxidants are the flavonoids, which are abundantly present in rooibos (aspalathus linearis) tea. Previous research has shown that rooibos tea has a performance-enhancing effect during physical exertion. Despite these positive findings during physical exertion, the effect of rooibos tea on muscle recovery is not yet well known. Moreover, the effects of antioxidants during and after physical exertion have almost only been studied in men. Therefore, the current study will investigate the effects of rooibos tea on inflammation, muscle damage and muscle pain in a female population, and whether the muscle recovery capacity can ultimately be accelerated.

Read the detailed description

On volunteers initial visit to the lab, they will be screened to assess their inclusion using the inclusion and exclusion criteria. Those who qualify for the study will be informed of the detailed procedures of the study. If they still decide to participate, they will be asked to read and sign the informed consent form. They will be asked to avoid taking NSAIDS during the course of the study. Participants will also be asked to refrain from the consumption of flavonoid-rich foods, drinks and supplements for 7 days prior to the test day. During the second visit (test day), baseline data such as body composition, anthropometrical variables, inflammatory markers (creatine kinase, TNF-α, IL-1 and IL-6), perceived muscle soreness and recover, and the quadriceps muscle functioning will be measured. The test will be done in the morning between 8:00 and 12:00 noon. To standardize the metabolic state of the participant during the testing sessions they will not be required to eat for at least two hours before testing. Moreover, participants will be required not to take caffeinated drinks and alcohol at least 12 hours before testing and not do any vigorous activities that have a rating of perceived exertion (RPE) more than (>) 12 on the Borg scale or any unusual exercise at least 24 hours before testing.

Participants will perform an 8 min warm-up of brisk walking on a treadmill (4-7 kph). They will then be subjected to the BIODEX exercise protocol. The protocol is composed of two exercise bouts (A and B), each of which comprises of 15 series of 12 maximum intermittent knee extensions conducted using the right leg on an isokinetic dynamometer with a 60 min break in between. During the 60 min break, the participants will cycle at 100 W on a bicycle ergometer (Monark) for 15 min in between bouts A and B, and then they rested in a semi-supine position for the next 45 min until bout B began. After completion of the exercise protocol, each participant will be asked to step down a total of four times from a bench 30.45 cm (1 ft.) high, alternating the leading leg between attempts to have each leg lead twice to assess the perceived muscle soreness using a 100-point visual analogue scale (VAS).

Participants will then be randomised into two (2) groups; the Aspalathus linearis group (AG) and the control group (CG). Participants will be asked to return after 24, 48 and 72 hours of the exercise. During each visit, the baseline measurements, perceived muscle soreness and muscle recovery will be repeated.

02

Conditions studied

  • Inflammation
  • Muscle Recovery
  • Muscle Soreness

Keywords

  • Aspalathus linearis
  • Rooibos
03

In context

Myalgia

282 studies on the registry are indexed under Myalgia; 43 are open to participants now.

This study's enrollment of 12 is below the median of 44 across 241 interventional studies indexed under Myalgia.

Browse Myalgia studies →

Lead sponsor

Hasselt University is the lead sponsor of 195 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Being a woman
  • Aged between 18-30 years
  • Must not engage regularly in more than 2 organized resistance training session per week or more than 5 h physical activity per week for the previous six months.
  • Answer "NO" to the seven questions of the Physical Activity Readiness Questionnaire plus (PAR-Q+) (Appendix B).

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating
  • Medication or undesirable alcohol consumption (>2 drinks per day) and smoking
  • Have any medical condition that can have a serious impact on their ability to exercise or report acute illness, chronic disease or any other medical problems during the health screening (Appendix A) session that did not necessarily exclude them from physical activity by the PAR-Q+
  • Currently using or have used vitamin and/or antioxidant supplementation for the last 2 months.
  • Has a history of clotting disorders and are currently on non-steroidal anti-inflammatory drugs or anti-coagulants
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Rooibos

    Participants in the AG will consume the test drink (12 g per 1200 ml of pure green rooibos tea). Participants will be asked to return after 24, 48 and 72 hours of the exercise. During each visit, the baseline measurements, perceived muscle soreness and muscle recovery will be repeated.

    Other: Rooibos tea

  • Placebo comparator
    Control

    Participants in the control group will be asked to drink 1200 ml of water since rooibos has a very unique taste

    Other: Control

Interventions

  • OtherRooibos tea

    Participants will be subjected to 12 g of rooibos tea per 1200 ml of freshly boiled water

  • OtherControl

    Participants will be subjected to 12 g per 1200 ml of freshly boiled water which is equivalent to 6 cups of tea

06

What researchers measure

Primary outcomes

  1. Change in Serum creatine kinase from Baseline to 72 hours

    Blood samples will be collected at baseline and 72 hours

    Time frame: Baseline and 72 hours

  2. Change in perceived muscle soreness from Baseline to 72 hours

    A 10 point analogue scale will be used to assess the muscle soreness. The ratings on the scale are 0 = "no soreness or pain", 2 = "mild annoying pain", 4 = "Nagging, uncomfortable troublesome pain", 6 = "Distressing, miserable pain", 8 = "Intense, dreadful pain", and 10 = "the worst possible, unbearable, excruciating pain"

    Time frame: Baseline and 72 hours

  3. Change in perceived muscle recovery from Baseline to 72 hours

    The perceived exercise recovery will be assessed using the Perceived recovery status (PRS) scale. The PRS scale rates recovery from exercise from 1 to 10 with 1-3 representing poor recovery and anticipating poor performance, 4-6 consisting of moderate recovery and expecting normal performance, and 7-10 representing high recovery and expecting increased performance

    Time frame: Baseline and 72 hours

  4. Change in Tumor Necrosis Factor -alpha (TNF-α) from Baseline to 72 hours

    Blood samples will be collected at Baseline and 72 hours

    Time frame: Baseline and 72 hours

  5. Change in interleukin-6 (IL-6) from Baseline to 72 hours

    Blood samples will be collected at Baseline and 72 hours

    Time frame: Baseline and 72 Hours

Secondary outcomes

  1. Change in swelling at the quadriceps muscle from Baseline to 72 hours

    Quadriceps muscle swelling will be assessed using the thigh circumference measurement. The thigh circumference measurement will be done using the tape measure and performed to the nearest tenth of a centimeter. Two measurements within two millimeters of each other will be completed and averaged at each time point

    Time frame: Baseline and 72 hours

  2. Change in quadriceps contractile muscle functioning from Baseline to 72 hours

    Quadriceps contractile muscle functioning will be assessed using vertical jump test. Squat jumps will be executed with both hands clasped together firmly behind the back to minimize arm assistance for uniformity after warming up with 12 squat jumps of rising height. The participants will be told to keep their trunks as erect as they could

    Time frame: Baseline and 72 hours

07

Study locations

1 site
  • Biomedical Research Institute, Hasselt University
    Hasselt, Limburg 3500, Belgium
08

References and documents

Publications

  • Sousa M, Teixeira VH, Soares J. Dietary strategies to recover from exercise-induced muscle damage. Int J Food Sci Nutr. 2014 Mar;65(2):151-63. doi: 10.3109/09637486.2013.849662. Epub 2013 Nov 4. PubMed 24180469 ↗
  • Marnewick JL, Rautenbach F, Venter I, Neethling H, Blackhurst DM, Wolmarans P, Macharia M. Effects of rooibos (Aspalathus linearis) on oxidative stress and biochemical parameters in adults at risk for cardiovascular disease. J Ethnopharmacol. 2011 Jan 7;133(1):46-52. doi: 10.1016/j.jep.2010.08.061. Epub 2010 Sep 15. PubMed 20833235 ↗
  • Eijnde BO, Van Leemputte M, Brouns F, Van Der Vusse GJ, Labarque V, Ramaekers M, Van Schuylenberg R, Verbessem P, Wijnen H, Hespel P. No effects of oral ribose supplementation on repeated maximal exercise and de novo ATP resynthesis. J Appl Physiol (1985). 2001 Nov;91(5):2275-81. doi: 10.1152/jappl.2001.91.5.2275. PubMed 11641371 ↗
  • Laurent CM, Green JM, Bishop PA, Sjokvist J, Schumacker RE, Richardson MT, Curtner-Smith M. A practical approach to monitoring recovery: development of a perceived recovery status scale. J Strength Cond Res. 2011 Mar;25(3):620-8. doi: 10.1519/JSC.0b013e3181c69ec6. PubMed 20581704 ↗

Individual participant data

Plan to share: Yes — All Individual Participant Data (IPD) that will be published will be shared

Supporting information: Study protocol, Sap, Icf

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06561750
Lead sponsor
Hasselt University
Responsible party
Daniel Afrifa (Principal Investigator, Hasselt University) — Principal investigator
First posted
Aug 20, 2024
Start date
Nov 1, 2023
Primary completion
Jan 30, 2024
Completion
Jan 30, 2024
Last update
Aug 20, 2024

Study contacts

Daniel Afrifa
principal investigator · Hasselt University (HasseltU)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion